FDA approves Roche drug for late-stage breast cancer
WASHINGTON (Reuters) – U. S. health regulators approved a new drug made by Swiss drugmaker Roche Holding AG for some patients with late-stage metastatic breast cancer who fail to respond to other therapies. The U. S. Food and Drug Administration said on Friday it had approved Kadcyla, also known as ado-trastuzumab emtansine, for patients whose cancer cells contain increased amounts of a protein known as HER2. The drug’s label will carry a boxed warning, the most serious possible, of the Kadcyla’s potential to cause liver and heart damage or even death. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply